Roche Holding Shares Show Undervaluation Despite Strong Multi-Year Gains

Roche Holding AG shares appear undervalued by multiple metrics despite delivering strong multi-year returns, with discounted cash flow models suggesting the stock could be worth significantly more than current trading levels. The pharmaceutical and diagnostics giant recently closed at CHF 358.80 to CHF 360.00, with returns of 22.3% over one year and 50.7% over three years, while scoring 5 out of 6 on valuation check frameworks that indicate potential undervaluation.

A discounted cash flow model using a 2 Stage Free Cash Flow to Equity approach estimates intrinsic value at CHF 875.58 to CHF 887.22 per share, implying the stock is approximately 59% undervalued compared to recent prices. The model is based on latest twelve-month free cash flow of CHF 13.6 billion, with projected free cash flow reaching CHF 22.0 billion to CHF 22.3 billion by 2030.

On price-to-earnings metrics, Roche currently trades at a P/E ratio of 22.16x to 22.24x, which sits slightly above the pharmaceuticals industry average of 21.22x to 22.24x but well below peer group averages ranging from 54.85x to 86.80x. The company's proprietary "Fair Ratio" is estimated at 42.00x to 42.62x, suggesting the shares screen as undervalued on an earnings multiple basis.

In 2025, Roche reported core earnings per share growth of 11% at constant exchange rates, reaching 19.46 CHF diluted. The company's equity attributable to shareholders rose steadily from 30.60 billion CHF in 2021 to 42.48 billion CHF in 2025, while dividends increased annually from 9.30 CHF in 2021 to 9.80 CHF in 2025, with a dividend yield of 2.9% in 2025.

Roche operates in two primary segments: pharmaceuticals and diagnostics. The pharmaceuticals division focuses on oncology, immunology, infectious diseases, ophthalmology, and neuroscience, while diagnostics provides solutions for professional and molecular testing. The company's pipeline includes potential blockbuster drugs in development, with specific focus on CT 388 in obesity, giredestrant for breast cancer, and fenebrutinib in multiple sclerosis, along with several Phase III readouts expected in 2026.

Recent product advancements include the cobas eplex respiratory pathogen panel 3, which enables rapid identification of multiple respiratory viruses and bacteria from one sample. The company generates substantial revenue from North America, Europe, and emerging markets, with North America representing a core market driving significant sales in pharmaceuticals and diagnostics.

On March 10, 2026, shareholders approved the exchange of non-voting equity securities for participation certificates, aligning rights with bearer shares. The stock's price-to-earnings ratio was 21 for shares in 2025, reflecting what analysts consider a balanced valuation in the pharmaceutical sector.

One analysis pegs fair value at CHF 430.01 versus a recent close of CHF 322.30, suggesting undervaluation, while over the past year, shares delivered a 10.30% total return with a 12.77% discount to the CHF 363.47 analyst target. Bull case narratives point to fair values around CHF 430 per share, highlighting Roche's large scale across pharmaceuticals and diagnostics, along with recent full year 2025 results that include steady reported revenue and profit.